300 North Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

300 North Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$294K	Sell	2,454 -59,951	-96%	-$7.16M	1.8%	31
2015 Q1	$6.52M	Sell	62,405 -1,345	-2%	-$136K	1.43%	19
2014 Q4	$6.18M	Buy	63,750 +4,474	+8%	+$415K	1.42%	24
2014 Q3	$4.63M	Buy	59,276 +34,174	+136%	+$2.2M	1.23%	27
2014 Q2	$1.59M	Buy	25,102 +7,180	+40%	+$427K	0.39%	79
2014 Q1	$1.2M	Buy	17,922 +14,602	+440%	+$1.13M	0.31%	79
2013 Q4	$214K	Hold	3,320	–	–	0.06%	102
2013 Q3	$213K	Buy	+3,320	New	+$165K	0.05%	116

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

300 North Capital's ALNY Position: Q2 2015 in Review

300 North Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 96% in Q2 2015, selling an estimated $7.16M and leaving 2,454 shares worth $294K. The position accounts for 1.8% of the portfolio, ranked #31.

300 North Capital first reported a position in ALNY in Q3 2013 and has held it in 8 quarters since. The position peaked at $6.52M in Q1 2015. 278 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

300 North Capital held 2,454 shares of Alnylam Pharmaceuticals worth $294K as of Q2 2015.
300 North Capital sold 59,951 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $7.16M.
Alnylam Pharmaceuticals made up 1.8% of 300 North Capital's portfolio in Q2 2015, its #31 holding.
300 North Capital first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 8 quarters since.
300 North Capital's Alnylam Pharmaceuticals position peaked at $6.52M in Q1 2015.
278 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.